VALNEVA (EPA:VLA) | WebDisclosure

Basculer en Français

10069	Companies
205847	Keywords
136110	Articles
109148	Press releases

Home
Companies
VALNEVA

PRESS RELEASE

published on 06/05/2024 at 07:00, 1 year 9 months ago

Valneva annonce la mise à disposition des documents préparatoires à son Assemblée Générale Mixte et une évolution de son équipe de direction
Valneva annonce la mise à disposition des documents préparatoires à son Assemblée Générale Mixte et une évolution de son équipe de direction

Documents Préparatoires Valneva Assemblée Générale Mixte Équipe De Direction Kendra Wergin
BRIEF

published on 05/21/2024 at 07:05, 1 year 10 months ago

Valneva nomme le Dr Hanneke Schuitemaker comme Directeur Scientifique

Nomination R&D Valneva Dr Hanneke Schuitemaker Vaccins
BRIEF

published on 05/21/2024 at 07:05, 1 year 10 months ago

Valneva appoints Dr Hanneke Schuitemaker as Scientific Director

Nomination R&D Valneva Vaccines Dr Hanneke Schuitemaker
PRESS RELEASE

published on 05/21/2024 at 07:00, 1 year 10 months ago

Valneva annonce la nomination du Dr Hanneke Schuitemaker en tant que Directeur Scientifique
Valneva annonce la nomination du Dr Hanneke Schuitemaker en tant que Directeur Scientifique, renforçant ainsi son équipe de direction. Le Dr Schuitemaker apportera son expertise en R&D pour développer des solutions vaccinales innovantes

R&D Valneva Dr Hanneke Schuitemaker Vaccins Directeur Scientifique
PRESS RELEASE

published on 04/18/2024 at 16:01, 1 year 11 months ago

Original-Research: Valneva (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research bestätigt Kaufempfehlung für Valneva SE mit Kursziel von €8,60 nach positiven Ergebnissen und Schuldenerlass. Analyse von Analyst Simon Scholes, CFA

Research Update Kaufempfehlung Valneva Simon Scholes Schuldenerlass
BRIEF

published on 04/12/2024 at 10:42, 1 year 11 months ago

Upbeat Valneva Research Update from First Berlin Equity Research Maintains BUY Rating

First Berlin Equity Research Buy Recommendation Financial Strategy Valneva Lyme Disease Vaccine
BRIEF

published on 04/12/2024 at 10:42, 1 year 11 months ago

La mise à jour optimiste de Valneva Research issue de First Berlin Equity Research maintient sa note d'achat

Stratégie Financière Recommandation D'achat Valneva Première Recherche Sur Les Actions À Berlin Vaccin Contre La Maladie De Lyme
PRESS RELEASE

published on 04/12/2024 at 10:37, 1 year 11 months ago

Original-Research: Valneva (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research reaffirms Buy rating on Valneva with a target price of €8.60, following positive guidance revisions and debt extension

First Berlin Equity Research BUY Rating Debt Extension Valneva EUR 8.60
PRESS RELEASE

published on 02/29/2024 at 17:26, 2 years ago

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research bestätigt Buy-Empfehlung für Valneva SE und senkt Kursziel auf €8.60. Neue Analyse zeigt starkes Umsatzwachstum und erweiterte Cash-Position

First Berlin Equity Research Kursziel Umsatzwachstum Buy-Empfehlung Valneva SE
BRIEF

published on 02/27/2024 at 16:01, 2 years ago

First Berlin mise à jour sa recommandation sur Valneva avec un objectif de cours ajusté

First Berlin Equity Research Recommandation D'achat Objectif De Cours Valneva Simon Scholes

Accesswire

Published on 03/23/2026 at 22:40, 28 minutes ago

Troubadour Announces Withdrawal of Non-Brokered Private Placements
Published on 03/23/2026 at 22:30, 38 minutes ago

Gregory J. Leia Sells Shares in Waskahigan Oil & Gas Corp
Published on 03/23/2026 at 22:00, 1 hour 8 minutes ago

Hillcrest Participates in APEC 2026 and Announces Shares for Debt Offering
Published on 03/23/2026 at 21:18, 1 hour 50 minutes ago

Amdocs Announces Appointment of Shimie Hortig to the Board of Directors Upon Shuky Sheffer's Retirement as Director and Chief Executive Officer
Published on 03/23/2026 at 14:05, 9 hours 3 minutes ago

Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders

View all ACCESSWIRE

EQS Group

Published on 03/23/2026 at 22:05, 1 hour 3 minutes ago

DeFi Technologies Provides Update on Timing of Annual Filings
Published on 03/23/2026 at 21:05, 2 hours 3 minutes ago

Abivax annonce ses résultats financiers pour l’exercice 2025 et fait le point sur l’avancement de ses activités
Published on 03/23/2026 at 21:05, 2 hours 3 minutes ago

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
Published on 03/23/2026 at 21:00, 2 hours 8 minutes ago

Persistent Appoints Ruchi Kulhari as Executive Vice President - Enterprise Strategy & Execution
Published on 03/23/2026 at 20:55, 2 hours 13 minutes ago

Ordering Both ESR and CRP Lab Tests Could Save Hospitals Millions Per Year -- New Study Challenges Notion the Tests are Interchangeable

Les Echos

Published on 03/23/2026 at 19:08, 4 hours ago

Reporting on share buyback transactions carried out between March 16 and March 20, 2026
Published on 03/23/2026 at 19:08, 4 hours ago

Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 16 et le 20 mars 2026
Published on 03/23/2026 at 18:37, 4 hours 31 minutes ago

ALTAREA : Déclaration d’opérations sur actions propres
Published on 03/23/2026 at 17:45, 5 hours 23 minutes ago

ENGIE will build, own and operate its largest onshore wind farm worldwide in Egypt
Published on 03/23/2026 at 17:45, 5 hours 23 minutes ago

En Égypte, ENGIE va construire et exploiter son plus grand parc éolien terrestre au monde

View all LES ECHOS COMFI WIRE